Xeris Biopharma Holdings Inc (XERS)
3.06
-0.09
(-2.86%)
USD |
NASDAQ |
Nov 14, 16:00
3.05
-0.01
(-0.33%)
After-Hours: 17:43
Xeris Biopharma Holdings Research and Development Expense (Quarterly): 5.759M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 5.759M |
| March 31, 2024 | 7.821M |
| December 31, 2023 | 6.382M |
| September 30, 2023 | 5.034M |
| June 30, 2023 | 6.087M |
| March 31, 2023 | 4.838M |
| December 31, 2022 | 4.955M |
| September 30, 2022 | 6.043M |
| June 30, 2022 | 3.718M |
| March 31, 2022 | 6.25M |
| December 31, 2021 | 10.08M |
| September 30, 2021 | 5.663M |
| June 30, 2021 | 5.383M |
| March 31, 2021 | 4.032M |
| December 31, 2020 | 5.11M |
| Date | Value |
|---|---|
| September 30, 2020 | 3.876M |
| June 30, 2020 | 5.289M |
| March 31, 2020 | 6.646M |
| December 31, 2019 | 12.42M |
| September 30, 2019 | 15.52M |
| June 30, 2019 | 19.33M |
| March 31, 2019 | 13.17M |
| December 31, 2018 | 12.39M |
| September 30, 2018 | 10.88M |
| June 30, 2018 | 8.677M |
| March 31, 2018 | 8.712M |
| December 31, 2017 | 6.578M |
| September 30, 2017 | 5.725M |
| June 30, 2017 | 4.201M |
| March 31, 2017 | 3.662M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.718M
Minimum
Jun 2022
12.42M
Maximum
Dec 2019
6.073M
Average
5.663M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Zevra Therapeutics Inc | 10.52M |
| NovaBay Pharmaceuticals Inc | 0.009M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |
| Theriva Biologics Inc | 2.953M |